MedTrace Logo

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

NCT06092047 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-16

No results posted yet for this study

Summary

This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.

Conditions

  • CD19-positive Relapsed or Refractory B-cell Malignancies

Interventions

BIOLOGICAL

UTAA09 cells for infusion

Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.

DRUG

Fludarabine

30 mg/m\^2/day×4 days

DRUG

Cyclophosphamide

1000 mg/m\^2/day×3 days

Sponsors & Collaborators

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xingbing Wang, MD · The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-07-31
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06092047 on ClinicalTrials.gov